Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 14Multiple Myeloma 11Lymphoma 11Breast Neoplasms 10Melanoma 7Neoplasm Metastasis 6Colorectal Neoplasms 6Sarcoma 5Ovarian Neoplasms 5Lung Neoplasms 5Leukemia 5Colonic Neoplasms 5Carcinoma, Hepatocellular 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neuroblastoma 3Neoplasms, Plasma Cell 3Mesothelioma, Malignant 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Glioblastoma 3

Interventions

golimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × NIH × Diabetes Mellitus, Type 1 × Clear all
NCT04729296 2021-12-02

Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 2 Withdrawn

Diabetes Mellitus, Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡